News

These clinical data were presented today in an oral presentation at the 1st European ATTR Amyloidosis Meeting for Patients and Doctors being held November 2-3, 2017 in Paris,

Pursuant to the Sublicense Agreement, Xenetic granted to Baxalta the right to grant a nonexclusive sublicense to certain patents related to the Company’s PolyXenInpex technology that were previously

The research collaboration and license agreement between the partners pertains to the discovery and development of GalXC RNAi therapeutics, with an initial focus on NASH. A chronic liver

Anoro Ellipta is a combination of two bronchodilators in a single dry powder inhaler, the Ellipta. It includes umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI),

Kymriah is a novel immunocellular therapy and a one-time treaent that uses a patient's own T cells to fight cancer. The submission is based on results from the

RBP-6000 is an investigational once-monthly injectable buprenorphine formulation in the ATRIGEL delivery system for the treatment of adults with moderate-to-severe OUD, as part of a complete treatment plan

The objective of the Elaris EM­III and Elaris EM­IV extension studies was to assess the long-term safety and efficacy of elagolix for the management of endometriosis with associated pain..

In 1984, the partnership had formed Kirin-Amgen to fund the global development of Epogen (epoetin alfa). Later, Kirin-Amgen also involved in the development of Neupogen, Neulasta (pegfilgrastim), Aranesp

The merger will result in a combined company, Vaxart, Inc., focused on developing orally-delivered therapeutics and prophylactics to address a variety of viral infections. “We are thrilled with